Korea Kolmar Received KFDA Approvals on Bioequivalence for Its Generics

Published: 2004-12-22 06:57:00

Updated: 2004-12-22 06:57:00

Korea Kolmar, a domestic company specialized in cosmetics contract manufacturing, has recently received approvals from the Korea Food and Drug Administration (KFDA) for pharmaceutical bioequivalence on its three generic products containing active ingredients of glimepiride, meloxicam, and loxopro...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK